PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced its participation at the American Association of Cancer Research (AACR) Annual Meeting 2023 being held from April 14-19 at the Orange County Convention Center in Orlando, Fla.
PhenomeX to Participate in American Association of Cancer Research Annual Meeting 2023 Read More »
M2GEN , an oncology-focused health informatics solutions company, today announced its participation as a presenter, exhibitor, and research partner at the American Association for Cancer Research (AACR) Annual Meeting April 14-19, 2023.
At the World Vaccine Congress, antimicrobial resistance as a global health crisis grabbed top billing.
World Vaccine Congress Panel Highlights Exigency of AMR Global Health Crisis Read More »
Select Medical Holdings Corporation (“Select Medical”) (NYSE: SEM), will release the financial results for its first quarter ended March 31, 2023 on Thursday, May 4, 2023 after the market closes.
Seagen Inc. (Nasdaq: SGEN) today announced that it will report its first quarter 2023 financial results on Thursday, April 27, 2023.
Seagen to Report First Quarter 2023 Financial Results on April 27, 2023 Read More »
BridgeBio Pharma, Inc. today announced that on March 7, 2023, the compensation committee of BridgeBio’s board of directors granted five new employees restricted stock units for an aggregate of 25,900 shares of the Company’s common stock.
Following the U.S. Food and Drug Administration’s decision , Covis Pharma Group (“Covis”) is effectuating the withdrawal of Makena ® (hydroxyprogesterone caproate injection), which has been the only treatment approved to reduce the risk of preterm birth in pregnant women who have had a prior spontaneous preterm birth.
Covis Statement on FDA Decision to Withdraw Approval of Makena® Read More »
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on April 5, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 22,000 shares of its common stock to three new employees, consisting of stock options to purchase
Merck, known as MSD outside of the United States and Canada, and Eisai provided updates on two Phase 3 trials, LEAP-003 and LEAP-017 investigating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai.
Mabwell, an innovative biopharmaceutical company with the whole industry chain layout, announced its Nectin-4 targeted site-specific ADC asset demonstrated promising clinical data.
China’s First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released Read More »
